This meeting is organised and funded by Novartis Pharmaceuticals UK Ltd and is intended for UK healthcare professionals only.
When Should I Refer a Child with Neuromuscular symptoms:
A Case Study in Spinal Muscular Atrophy (SMA) for the
Yorkshire and East Midlands Area
17th May 2024 | 13:30 – 15:30 BST
UK | May 2024 | 439930
Your attendance at the event is governed by our Healthcare Professional Event Attendance Terms. By attending the event, you are agreeing to be bound by such terms.
By clicking the below link (www.mhra.gov.uk/yellowcard) you will leave this Novartis-associated website. This link will take you to a website to which our privacy policy does not apply.
You are solely responsible for your interactions with that website.
Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/
Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report
If you have a question about a product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com